Global Release | 'Blue Book on Global Stem Cell Industry Development 2026' (Chinese and English Version) - Access Method Included

Stem cells are undifferentiated cells with the potential for self-renewal and multi-directional differentiation. Based on differentiation potential, they can be divided into totipotent, pluripotent, multipotent, oligopotent, and unicellular stem cells. Based on tissue origin, they can be classified as embryonic stem cells, adult stem cells, and induced pluripotent stem cells. Through mechanisms such as differentiation replacement, paracrine signaling, immune regulation, and direct cell transfer, stem cell therapies can restore, replace, and regenerate damaged cells, tissues, or organs, and have been applied in areas such as neuroscience, metabolism and cardiovascular systems, immunity, genetic functional deficiencies, infections, and respiratory and renal regeneration.

Clinical and commercial translation of stem cell therapies continue to progress globally. As of the time of report compilation, more than 30 stem cell products had been approved for market release. Stem cell therapies have achieved significant clinical progress in areas such as graft-versus-host disease, heart failure, Parkinson's disease, knee osteoarthritis, stroke, liver cirrhosis and liver failure, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, thrombocytopenia after tumor treatment, and chronic periodontitis.

iPSCs are obtained through somatic cell reprogramming, possessing pluripotency and a wide range of cell sources, making them valuable for disease modeling, drug screening, and cell replacement therapy; ESCs have the ability for long-term self-renewal and triploblastic differentiation, enabling the creation of standardized, scaled异体 product forms; MSCs, relying on immune regulation, anti-inflammatory effects, paracrine signaling, and tissue repair functions, are a technical approach with high maturity and broad application scope in clinical translation.

In terms of the manufacturing system, the production of stem cell preparations begins with strict donor screening to ensure the safety of cell sources, followed by tissue collection and transportation. The collected tissues are isolated, purified, and cultured directly, and their identity and quality are confirmed through cell identification and characterization. Then, a cell bank system consisting of a main cell bank and working cell bank is established, or the MCB is directly used for production, providing uniform and stable starting materials for production. During production, cells are revived from the cell bank and scaled up on a closed automated platform that meets GMP requirements, achieving large-scale expansion. After harvesting, the cells are washed and proceed to formulation. Finally, the product must pass comprehensive quality checks, confirming that indicators such as cell viability, phenotype, biological efficacy, differentiation potential, and microbial safety meet standards before being released, and the finished product is safely delivered to clinical use points through validated storage and transportation methods. Large-scale expansion and preparation, closed automated production, validated storage and transportation, and quality control throughout the entire process are key aspects ensuring the consistency, safety, and clinical usability of stem cell preparations.

Global population aging, the increasing burden of degenerative diseases and chronic illnesses, and the limitations of traditional treatments in areas such as cancer, neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and rare diseases collectively form the core clinical needs for the development of the stem cell industry. At the same time, continuous breakthroughs in gene editing, iPSC reprogramming, three-dimensional culture, biomaterials, organoids, artificial intelligence, and automation technologies provide a technical foundation for the construction of engineered cells, targeted differentiation, standardized expansion, and quality consistency control.

Regulation and industrial ecosystem are also continuously improving. Major regulatory bodies such as the FDA, EMA, and NMPA have successively issued or updated technical guidelines and review standards for stem cell products. Mechanisms such as advanced regenerative medicine recognition and breakthrough therapy recognition provide more efficient development paths for products with clinical advantages. The CDMO system, ultra-low temperature cold chain logistics, and clinical research center networks are continuously maturing, combined with continuous entry of venture capital, private equity, and industrial capital, providing support for stem cell therapies to move from laboratory research to clinical application and commercialization.

Looking ahead, the industry will show the following trends: indications will expand from existing advantageous areas to diseases such as musculoskeletal, neurodegenerative, metabolic and liver diseases, and cardiovascular and cerebrovascular diseases; business models will evolve towards 'central laboratory production + regional infusion center network', full-course service, and global multi-center development; regulatory science and ethical frameworks will be further refined; and the competitive landscape will be driven by mergers and acquisitions between multinational pharmaceutical companies and platform innovations of biotech companies.

The Blue Book summarizes leading Chinese stem cell companies as case studies, introducing their business layouts, core technology platforms, product pipelines, and clinical translation capabilities, presenting the differentiated development paths of Chinese enterprises in areas such as stem cell drug research and development, large-scale manufacturing, clinical translation, and industrial chain services.